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Abstract
Human mesoangioblasts are currently in a phase I/II clinical trial for the
treatment of patients with Duchenne muscular dystrophy. However, limitations
associated with the finite life span of these cells combined with the significant
numbers of mesoangioblasts required to treat all of the skeletal muscles in
these patients restricts their therapeutic potential. Induced pluripotent stem cell
(iPSC)-derived mesoangioblasts may provide the solution to this problem.
Although, the idea of using iPSC-derived cell therapies has been proposed for
quite some time, our understanding of how the immune system interacts with
these cells is inadequate. Herein, we show that iPSC-derived mesoangioblasts
(HIDEMs) from healthy donors and, importantly, limb-girdle muscular dystrophy
2D patients exert immunosuppressive effects on T cell proliferation.  Interferon
gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α) play crucial roles in
the initial activation of HIDEMs and importantly indoleamine 2,3 dioxygenase
(IDO) and prostaglandin E2 (PGE-2) were identified as key mechanisms
involved in HIDEM suppression of T cell proliferation. Together with recent
studies confirming the myogenic function and regenerative potential of these
cells, we suggest that HIDEMs could provide an unlimited alternative source for
mesoangioblast-based therapies.
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Introduction
Preclinical models of muscular dystrophy in both mouse 
(α-sarcoglycan-null, dysferlin-null and mdx)1–4 and dog (golden 
retriever muscular dystrophy)2 provided evidence that mesoangio-
blasts have the capacity to functionally ameliorate the dystrophic 
phenotype. Based on these data, human allogeneic HLA-identical 
mesoangioblasts are in a phase I/II clinical trial for the treatment 
of paediatric patients affected by Duchenne muscular dystrophy 
(DMD; EudraCT no. 2011-000176-33). However, human mesoan-
gioblasts have a finite lifespan in culture and the need for large cell 
numbers to treat each patient may impact the therapeutic efficacy 
of this approach, especially if this treatment should be extended 
to adults. To address and overcome these issues, the concept of 
deriving patient-specific induced pluripotent stem cells (iPSCs) that 
could serve as a platform for the genetic correction of autologous 
cell therapies in the future is being explored5.
Developments in the generation of iPSCs have advanced signifi-
cantly in the past 6 years6,7; however, concerns related to potential 
tumorigenicity, incomplete and inefficient terminal differentiation8, 
as well as immunogenicity of iPSCs9 and in particular their differ-
entiated progeny remains to be fully elucidated. Immune rejection 
represents a significant hurdle not just for allogeneic cell therapies, 
but for all cell therapy approaches, and questions surrounding the 
potential immunogenicity of iPSCs and their derivatives have been 
largely overlooked. A recent study provides evidence that syngeneic 
mouse iPSCs are more immunogenic than their embryonic stem cell 
(ESC) counterparts9. Immune responses against the integrated viral 
vectors9 as well as allogeneic10 and mutated mitochondrial genome 
after long term culture11 of iPSCs have been reported. Moreover, 
rejection of syngeneic mouse iPSCs following transplantation 
in vivo into mice9 highlights the fact that even autologous iPSCs can 
be recognised by the immune system and will be subject to stand-
ard rejection mechanisms12,13. Therefore, characterising the interac-
tions between iPSC-derived differentiated cells and immune cells 
and determining whether or not these cells are recognised and 
rejected by the immune system is critically important.
To explore these possibilities, we utilised a novel protocol to derive 
mesoangioblast-like cells (human iPSC-derived mesoangioblasts: 
HIDEMs) initially from healthy iPSCs and subsequently from 
iPSCs reprogrammed from skeletal muscle cells of Limb-Girdle 
Muscular Dystrophy, Type 2D (LGMD2D) patients14. These cells, 
as expected, exert similar myogenic potential as normal mesoangio-
blasts, which makes them candidates for future clinical application. 
Here, we examined the effect of HIDEMs derived from both healthy 
donors and LGMD2D patients on immune cells in vitro and com-
pared them with conventionally generated mesoangioblasts from 
healthy donors. Importantly, we demonstrate that HIDEMs from 
both sources do not induce, but rather suppress mitogen-driven 
T cell proliferation in vitro. Moreover, consistent with our findings 
for adult skeletal muscle-derived human mesoangioblasts15, HIDEMs 
mediate their immune suppressive effects through indoleamine 2,3 
dioxygenase (IDO) and prostaglandin E2 (PGE-2).
Materials & methods
Cell culture
Human mesoangioblasts were isolated from adult skeletal muscle 
as previously described16. The HIDEM lines utilized in this study 
were generated from human iPSCs derived from either healthy 
donors (HIDEMs #1) or patients affected by limb-girdle muscular 
dystrophy 2D (LGMD2D Pt.3 HIDEMs) and are described in detail 
in a recent publication14. Both cell types were cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM; PAA) containing 10% FBS 
(Gibco), 2 mM glutamine (PAA), 0.1 mM β-mercaptoethanol (Sigma-
Aldrich), 1% NEAA (PAA), 5 ng/ml human bFGF (Peprotech), 100 
IU ml–1 penicillin (PAA), 100 mg/ml–1 streptomycin (PAA), 1% 
insulin transferrin selenium X (ITSX) supplement (Gibco), 0.5 μM 
oleic and linoleic acids (Sigma-Aldrich), 1.5 mM Fe++ (Iron10 chlo-
ride tetrahydrate, Sigma; or Fer-In-Sol, Mead Johnson), 0.12 mM 
Fe+++ (Iron(III) nitrate nona- hydrate, Sigma; or Ferlixit, Aventis). 
Myogenic differentiation of mesoangioblasts and HIDEMs was 
performed as previously described14,16.
Human peripheral blood mononuclear cells (PBMCs) were isolated 
from buffy coats. PBMCs from 4 donors were used in this study. All 
PBMC cultures were carried out in RPMI 1640 (Sigma-Aldrich) 
supplemented with 10% FBS (Gibco), 1% v/v L-glutamine (PAA), 
0.05mM β-mercaptoethanol (Sigma-Aldrich) and 100 IU ml–1 peni-
cillin (PAA) and 100 mg/ml–1 streptomycin (PAA).
T cell proliferation assays
Proliferation of PBMCs was measured using the 5,6 carboxyfluo-
rescein diacetate succinimidyl ester (CFSE) dilution assay. PBMCs 
were labelled with 10μM CFSE (Invitrogen) in warm phosphate 
buffered saline (PBS) at room temperature. After 10 minutes, cells 
were washed in ice cold PBS. CFSE-abelled PBMCs (2.5 × 105/ml) 
were then seeded into 96-well round bottom plates with or without 
human anti-CD3/CD28 beads (Dynal-Life Technologies, UK) (0.5 
× 105/ml) in complete RPMI 1640 (Sigma-Aldrich). For suppres-
sor assays, mesoangioblasts/HIDEMs were seeded overnight in 96-
well round bottom plates in mesoangioblast/HIDEM cell culture 
medium. The medium was then replaced with complete RPMI 1640 
containing PBMC and anti CD3/CD28 beads where appropriate. 
Cells were harvested on day 6 and CFSE dilution was analysed 
by flow cytometry (FACSCantoTM II, BD Bioscience, UK). Actual 
numbers of CFSE-divided cells were calculated using counting 
beads (BD Biosciences, UK).
Flow cytometric analysis
Mesoangioblasts and HIDEMs were characterised for the following 
phenotypic surface markers: HLA-ABC, HLA-DR (BD Biosciences), 
CD105, CD73, CD49b (eBioscience) and CD146 (Biocytex). In 
addition, mesoangioblast expression of CD40 (BD Biosciences) 
and PD-L1 (eBioscience) as well as the HLA molecules were ana-
lysed before and after stimulation (24h) with the pro-inflam matory 
cytokines interferon gamma (IFN-γ), tumour necrosis factor alpha 
(TNF-α) or interleukin 1-beta (IL-1β) (Peprotech, UK). The effect 
of mesoangioblast on the expression of early activation markers on 
T cells was analysed by flow cytometry. Cells were harvested on 
day 3, 4, 5 and 6 and stained with anti-CD3, anti-CD25, anti-CD69 
and 7AAD (eBioscience).
Neutralising and blocking studies
Proliferation assays in the form of CFSE dilution were carried out 
as described above in the presence or absence of neutralising 
antibodies to IFN-γ (R&D Systems), TNF-α (eBioscience), isotype 
control (R&D Systems) or recombinant IL-1 receptor antagonist 
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Results
HIDEMs share the same immuno-phenotype and myogenic 
potential with mesoangioblasts
Cultured HIDEM lines, HIDEMs #1 and LGMD2D Pt.3 HIDEMs, 
together with mesoangioblast lines XY24TL and XY27FD were 
characterised for their surface expression of pericyte makers CD73, 
CD105, CD49b, CD146, and HLA molecule HLA-ABC and HLA-
DR. HIDEM lines and mesoangioblast lines expressed all of the 
aforementioned pericyte markers as well as HLA-ABC and low 
level expression of HLA-DR, indicating that these cells share the 
same phenotype (Figure 1A). HIDEM cells were also character-
ized for their myogenic potential with differentiation into skeletal 
(IL-1RA) (eBioscience) at concentrations of 0.5, 1.0 and 2.0 ug/ml. 
Inhibitors of IDO-1-Methyl-L-tryptophan (1MT) (Sigma-Aldrich) 
(0.5 mM), and of Cox-2: NS-398 (Calbiochem, UK) (1.0 uM) were 
used in this study.
Statistical methods
Data were analysed using the statistical software Prism (version 5; 
GraphPad Software) and are reported as mean +/- standard error 
(SE). The unpaired Student t test was performed to compare 2 mean 
values. Otherwise, data were analysed using a two-way ANOVA 
with Bonferonni’s post-test and p values <0.05 were considered 
statistically significant.
B
A
%
M
ax
HLA-ABC CD49b CD105 HLA-DRCD146 CD73
XY24TL
XY27FD
HIDEMs #1
LGMD2D Pt.3
HIDEMs
XY24TL XY27FD HIDEMs #1 LGMD2D Pt.3
HIDEMs
Figure 1. HIDEM and mesoangioblast surface marker phenotype and differentiation capabilities. Healthy donor HIDEM line #1 and 
LGMD2D HIDEMs from patient no. 3 (HIDEMs Pt.3) and mesoangioblasts XY24TL and XY27FD were analysed for their surface marker 
expression of HLA-ABC, HLA-DR, CD105, CD73, CD49b and CD146 (A). Mesoangioblasts were stained with fluorochrome-labelled antibodies 
against the above markers (shown in red) as well as isotype matched control antibodies (shown in blue) followed by flow cytometric analysis. 
All four cell lines were also induced for myogenic differentiation followed by immunostaining of myocyte/myotube marker Myosin Heavy Chain 
(red). Cell nuclei were counter stained with Hoechst (blue). Scale bar = 100 µm (B).
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myocytes/myotubes. Myogenic differentiation was observed in 
HIDEM lines, like in mesoangioblasts, by immunostaining for the 
striated muscle specific marker myosin heavy chain (Figure 1B), with 
the only difference that HIDEM terminal differentiation needed the 
expression of the myogenic regulator MyoD, as recently reported14.
Mesoangioblasts do not provoke T cell proliferation in vitro, 
even in the presence of inflammatory mediators
It has been shown that allogeneic stem cells enjoy some level of 
immune privilege17–21. However, the general consensus is that dif-
ferentiated cells tend to be more immunogenic than undifferentiated 
stem cells as demonstrated by studies using embryonic stem 
cells18,22. Thus, it was important to compare the immunogenicity of 
HIDEMs with that of mesoangioblasts derived from conventional 
adult muscle under basal (see above) or simulated inflammatory 
conditions. Following stimulation with the pro-inflammatory 
cytokines IFN-γ, TNF-α or IL-1β or a combination of these solu-
ble mediators, expression of HLA-ABC, HLA-DR, PD-L1 were 
increased after stimulation with IFN-γ, but not TNF-α or IL-1β 
(Figure 2A and 2B). Stimulation of HIDEMs and mesoangioblasts 
with IFN-γ and TNF-α or combinations of these cytokines induced 
low-level expression of CD40 (Figure 2A and 2B).
IFN-γ - + - - + + - +
TNF-α - - + - + - + +
IL-1β - - - + - + + +
IFN-γ - + - - + + - +
TNF-α - - + - + - + +
IL-1β - - - + - + + +
B
**
**
** **
** **
** ** **
PBMC + + + + + + + + + +
An CD3/28 - + - - - - - - - -
Meso 1:4 - - + + + + + + + +
Pre-s m :IFN-γ - - - + - - + + - +
:TNF-α - - - - + - + - + +
:IL-1β - - - - - + - + + +
C
Ctrl
IFN-γ
TNF-α
IL-1β
IFN-γ + TNF-α
IFN-γ + IL-1β
TNF-α + IL-1β
ALL
Iso Ctrls
PD-L1 HLA-ABC HLA-DR CD40
A
Figure 2. HIDEMs and mesoangioblasts fail to induce T cell proliferation in vitro. HIDEMs and mesoangioblasts were stimulated with 
IFN-γ, TNF-α or IL-1β (20ng/ml) for 24h. Cells were trypsinized and washed, followed by surface staining for HLA-ABC, HLA-DR, CD40, PD-
L1 or fluorochrome matched isotype controls and analysis by flow cytometry. Representative histograms of HIDEMs #1 are presented here 
(A). Data are represented as mean (+/- SE) median fluorescence intensity of the markers examined over 4 replicates. **p<0.01 (B). CFSE-
labelled PBMCs were stimulated with anti CD3/CD28 beads (PBMC+B) as a positive control. Non-stimulated or cytokine stimulated HIDEMs/
mesoangioblasts (ratio 1:4) were co-cultured with PBMC for 6 days. CD3+ CFSE labelled 7AAD- cells were enumerated using counting beads 
(C). Experiments were carried out in duplicates. n=4.
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Change of surface marker expression of Mesoangioblasts/
HIDEMs upon pro-inflammatory stimulation
http://dx.doi.org/10.6084/m9.figshare.106723 
HIDEMs and mesoangioblasts fail to induce T cell proliferation 
in vitro
http://dx.doi.org/10.6084/m9.figshare.106724 
To examine their immunogenicity, HIDEMs and mesoangioblasts 
cultured under basal conditions or pre-stimulated with the pro-
inflammatory cytokines IFN-γ, TNF-α or IL-1β were co-cultured 
with allogeneic CFSE-labelled PBMCs. Neither HIDEMs nor mes-
oangioblasts induced CD3+ T cell proliferation (Figure 2C) in vitro 
after 6 days of co-culture. Furthermore, exposure of HIDEMs to 
pro-inflammatory cytokines did not alter this lack of T cell response 
(Figure 2C). Thus, T cells were unresponsive to allogeneic HIDEMs 
even after pre-stimulation with pro-inflammatory cytokines.
Both HIDEMs and mesoangioblasts suppress T cell 
proliferation in a dose-dependent manner, but do not interfere 
with T cell activation
Human mesoangioblasts have the capacity to modulate T cell pro-
liferation in vitro15. Here, we sought to determine whether HIDEMs 
could exert immune suppressive effects. All 4 cell lines potently 
suppressed CD3+ T cell proliferation in vitro in a dose-dependent 
manner (Figure 3A and 3B). Interestingly, HIDEMs from both 
healthy donors and patients showed greater suppressive potency 
compared to mesoangioblasts at the same cell:PBMC ratio. We 
therefore hypothesised that HIDEMs may alter T cell activation. 
The effect of HIDEMs/mesoangioblasts on the expression of early 
T cell activation markers (CD25 and CD69), was directly examined 
on PBMCs stimulated with anti-CD3/CD28 beads in the presence 
or absence of HIDEMs or mesoangioblasts. The percentage of T 
cells expressing CD25 and CD69 increased significantly between 
days 3 and 4 after stimulation as expected, and the presence 
of HIDEMs or mesoangioblasts inhibited the expression of CD69 
on day 3 but had no effect on days 4–6 (Figure 3C). Expression 
of CD25 was not significantly affected by HIDEMs or mesoan-
gioblasts at any time point examined (Figure 3C). Thus, although 
1:4
1:8
1:16
1:32
PBMC + An
CD3/CD28
PBMC
XY24TL XY27FD HIDEMs #1 LGMD2D Pt.3
A B
C
Figure 3. Mesoangioblasts suppress T cell proliferation in a dose-dependent manner without interfering with T cell activation. CFSE-
labelled PBMCs (5 × 104/well) were stimulated with anti CD3/CD28 beads (1 × 104/well) (P+B) in the presence or absence of HIDEMs/
mesoangioblasts at decreasing ratios (HIDEM/mesoangioblast:PBMC). On day 6, cells were harvested and stained with anti-CD3 and 7AAD, 
and analysed by flow cytometry. CFSE dilution was analysed on gated CD3+7AAD- cells. Representative histograms showing CD3+7AAD- 
cells with CFSE dilutions after co-culture with HIDEM/mesoangioblast (A). The percentage of CD3+CFSE dividing cells calculated for each 
group and compared to the positive control (P+B). *p<0.05 (B). Cells were harvested on day 3, 4, 5 or 6 and analysed for CFSE dilution and 
expression of CD25 and CD69. The number of CD3+7AAD- cells expressing CD25 or CD69 using counting beads and the % of CD25+ and 
CD69+ cells were calculated from the data (C). Experiments were carried out in duplicates. n=2. Unpaired t tests were used for statistical analysis.
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HIDEMs utilise both IDO and PGE-2 in the suppression of 
T cell proliferation
IDO and PGE-2 have been identified as key mechanisms in the 
modulation of T cell proliferation by mesoangioblasts. To test the 
hypothesis that IDO and PGE-2 are key pathways used by HIDEMs 
for modulating T cell proliferation, 1-Methyl-L-tryptophan (1MT) 
(an inhibitor of IDO) or NS-398 (1.0 μM) (a specific Cox-2 inhibitor) 
were added to T cell cultures containing HIDEMs or mesoangio-
blasts. Both inhibitors partially, but significantly, restored prolif-
eration, with 1MT having the most potent effect. Addition of both 
inhibitors showed an additive effect (Figure 5). Restoration of pro-
liferation mediated by the addition of NS-398 was significant in 
cultures containing HIDEMs, but not mesoangioblasts (Figure 5).
The presence of IDO and PGE-2 inhibitors reduce the 
suppression of T cell proliferation by Mesoangioblasts/HIDEMs
http://dx.doi.org/10.6084/m9.figshare.106729 
Discussion
The advent and unwavering development of iPSC technology makes 
autologous cell therapy and personalised gene therapy a realistic 
possibility for many degenerative and genetic diseases like muscu-
lar dystrophies. Nevertheless, a number of reports have raised con-
cerns on the overlooked possibility that iPSCs and their derivatives 
may be targeted by the immune system for various reasons9,10,23. The 
recent new development of human iPSC-derived mesoangioblasts 
may provide an unlimited source for mesoangioblast therapy for 
DMD, but understanding the immunogenicity of these cells is criti-
cally important for their successful application.
In the current study, we demonstrate that HIDEMs behave in a 
very similar manner to mesoangioblasts with regard to expression 
of HLA and co-stimulatory molecules, suppressive potency and 
mechanisms of action. We showed that HIDEMs are comparable 
to mesoangioblasts in their surface marker expression and that 
both cell populations respond to stimulation with pro-inflammatory 
cytokines consistently with increased expression of HLA-ABC, 
HLA-DR, PD-L1 and low level expression of CD40. Importantly, 
HIDEMs suppress T cell proliferation driven by anti-CD3/CD28 
stimulation in a similar dose-dependent manner as that of mes-
oangioblasts, but with increased potency. Comparable to mesoan-
gioblasts, HIDEMs did not alter the expression of early activation 
markers CD25 or CD69 on CD3+ T cells, a phenomenon also seen 
with immune-suppressive mesenchymal stromal cells (MSC)24.
An activation step involving IFN-γ or TNF-α was a prerequisite 
for HIDEM suppression of T cell proliferation as neutralisation of 
either cytokine significantly abolished the inhibitory effect. IDO 
and PGE-2 were identified as key mechanisms of action involved in 
HIDEM suppression of T cell proliferation. Overall, the immuno-
genicity and immunosuppressive capacity of HIDEMs was almost 
indistinguishable from that of their conventionally derived counter-
part, mesoangioblasts15. The only minor differences between these 
two cell populations were the increased immunosuppressive potency 
and sensitivity of HIDEMs to TNF-α and to the specific Cox-2 
HIDEMs exhibited more potent activity with respect to inhibition 
of T cell proliferation, they did not differentially impact T cell 
activation.
Mesoangioblasts and HIDEMs suppress T cell proliferation in a 
dose dependent manner
http://dx.doi.org/10.6084/m9.figshare.106725 
Mesoangioblasts and HIDEMs do not interfer with T cell 
activation
http://dx.doi.org/10.6084/m9.figshare.106726 
IFN-γ and TNF-α play important roles in the suppression of 
T cell proliferation by HIDEMs
As IFN-γ, TNF-α and IL-1β have been identified as key cytokines 
required for the activation of mesoangioblast immunosuppressive 
function in vitro15, we examined the importance of these pro-
inflammatory cytokines in the modulation of T cell proliferation by 
HIDEMs. Neutralising antibodies against IFN-γ at concentrations 
of 1.0 and 2.0 ug/ml significantly abolished the inhibitory effect 
mediated by HIDEMs and mesoangioblasts (Figure 4A). A similar, 
but weaker effect was observed in the presence of a neutralising 
antibody against TNF-α (2.0 ug/ml) for both cell types. Notably, 
a lower concentration of anti-TNF-α (1.0 ug/ml) partially restored 
T cell proliferation in the presence of HIDEMs, but not mesoangio-
blasts, suggesting that TNF-α may play a more important role in 
the suppressive function of HIDEMs compared to mesoangioblasts 
(Figure 4A). The addition of IL-1 receptor antagonist (IL-1RA) at 
concentrations of 0.5, 1.0 or 2.0 ug/ml did not restore T cell prolif-
eration in this case.
Neutralising antibodies against IFN-γ and TNF-α reduce the 
immunosuppressive capacity of Mesoangioblasts/HIDEMs
http://dx.doi.org/10.6084/m9.figshare.106727
Pre-stimulation with IFN-γ, TNF-α and IL-1β does not enhance 
the immunosuppressive effect of Mesoangioblasts/HIDEMs
http://dx.doi.org/10.6084/m9.figshare.106728 
Our previous study showed that pre-stimulation with IFN-γ, TNF-α 
or IL-1β does not enhance or abrogate mesoangioblast suppression 
of T cell proliferation in vitro. To test if this holds true for HIDEMs, 
cells were then pre-treated with IFN-γ, TNF-α, IL-1β, or combi-
nations of these cytokines for 24h before adding them to CFSE 
dilution assays to examine their immunosuppressive capacity. 
Pre-stimulation did not promote the suppressor capacity of HI-
DEMs or mesoangioblasts, compared to non-stimulated controls 
(Figure 4B). However, there was no significant loss of suppressor 
capacity by HIDEMs following stimulation with pro-inflammatory 
cytokines, similar to that observed for mesoangioblasts.
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Figure 4. IFN-γ and TNF-α play important roles in HIDEM and mesoangioblast suppression of T cell proliferation. CFSE-labelled PBMCs 
were stimulated with anti-CD3/CD28 beads in the presence of HIDEMs/mesoangioblasts (1:4) and neutralising antibodies against IFN-γ and 
TNF-α or irrelevant isotype control antibody (0.5, 1.0 and 2.0 µg/ml) or recombinant IL-1RA (0.5, 1.0 and 2.0 µg/ml). Cells were harvested on 
day 6 and stained with anti-CD3 and 7AAD. After gating on CD3+7AAD- the number of CFSE diluting cells were enumerated using counting 
beads. Data are represented as mean CD3+ CFSE diluted cell number +/- SE. *p<0.05, **p<0.01 (A). HIDEMs/mesoangioblasts were left 
untreated or were stimulated with IFN-γ, TNF-α or IL-1β (20ng/ml) for 24h before setting up co-cultures with CFSE labelled PBMCs. As a 
positive control, PBMCs were stimulated with anti CD3/CD28 beads. After 6 days cells were harvested and surface stained for CD3 and 
7AAD before analysis of CFSE dilution. CD3+CFSE diluted cell numbers were calculated using counting beads as before (B). Experiments 
were carried out in duplicates. n=4.
PBMC + + + + + + + + + +
An CD3/28 - + - - - - - - - -
Meso 1:4 - - + + + + + + + +
Pre-s m :IFN-γ - - - + - - + + - +
:TNF-α - - - - + - + - + +
:IL-1β - - - - - + - + + +
B
PBMC + + + + + + + + + + + + + + +
An CD3/28 - + + + + + + + + + + + + + +
Meso 1:4 - - + + + + + + + + + + + + +
An IFN-γ µg/ml - - - 0.5 1.0 2.0 - - - - - - - - -
An TNF-α µg/ml - - - - - - 0.5 1.0 2.0 - - - - - -
IL-1RA µg/ml - - - - - - - - - 0.5 1.0 2.0 - - -
Iso Ctrl Ab µg/ml - - - - - - - - - - - - 0.5 1.0 2.0
A
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PBMC + + + + + +
An CD3/28 - + + + + +
Meso 1:4 - - + + + +
1MT - - - + - +
NS-398 - - - - + +
PBMC + + + + + +
An CD3/28 - + + + + +
HIDEM 1:4 - - + + + +
1MT - - - + - +
NS-398 - - - - + +
Figure 5. IDO and PGE-2 are involved in HIDEMs suppression of T cell proliferation. CFSE-labelled PBMCs were stimulated with anti 
CD3/CD28 beads as before in the presence of HIDEMs/mesoangioblasts and inhibitors of IDO and Cox-2, (1-Methyl-L-trypyophan (1MT) 
(0.5 mM) and NS-398 (1.0 uM) respectively, or both. On day 6 cells were harvested and stained with anti-CD3 and 7AAD. Cells were gated 
on live CD3+ populations and analysed for CFSE dilution and the numbers of cells undergoing CFSE dilution were enumerated using counting 
beads, *p<0.05, **p<0.01. Experiments were carried out in duplicates. n=4.
inhibitor NS-398. Perhaps these three observations are linked and 
suggest that HIDEMs are more receptive to TNF-α, leading to the 
induction of enhanced levels of PGE-2 facilitating a more potent 
inhibition of T cell proliferation. Importantly, this study demon-
strates that iPSC derived cells (HIDEMs) display immunomodulatory 
functions equivalent to those of their tissue-derived counterpart, 
mesoangioblasts.
Gene therapy is an appealing approach to treat many hereditary dis-
eases such as DMD, and adeno-associated virus-based gene therapy 
trials showed promising results for LGMD2D patients25. However, 
problems associated with immunity to dystrophin and subsequent 
loss of transgene expression might limit the successful application 
of this approach26,27. The use of retro-/lenti-viral vector-based tech-
niques for the generation of iPSCs and for gene correction of their 
progeny means that cells derived from iPSCs using these technolo-
gies could face the same challenge. Nevertheless, HIDEMs have 
been derived in a complete viral integration-free setting14 and, 
although we have not examined their immunomodulatory function 
in vivo, the proven therapeutic value of iPSC-derived mesoangio-
blasts, combined with their potential immune suppressive charac-
teristics, means that HIDEMs are well placed to overcome some of 
the challenges facing iPSC-derived cell therapies.
Author contributions
OL contributed to conception and design, acquisition of data, analy-
sis and interpretation of data, drafting and revising the article. KE 
contributed to conception and design, analysis and interpretation of 
data, drafting and revising the article. RT contributed to acquisition 
Page 9 of 12
F1000Research 2013, 2:24 Last updated: 24 MAR 2014
Grant information
This research was supported by the European Community grant 
OptiStem (223098), European Research Council (GA 233263), The 
Wellcome Trust (082519/Z/07/Z) and Medical Research Council 
(87216).
The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
of data. GC contributed to revising the article. FST contributed to 
acquisition of data and revising the article. KJW contributed to con-
ception and design, analysis and interpretation of data, drafting and 
revising the article. All authors contributed to the final approval of 
the version to be published.
Competing interests
No competing interests were disclosed.
References
1. Sampaolesi M, Torrente Y, Innocenzi A, et al.: Cell therapy of alpha-sarcoglycan 
null dystrophic mice through intra-arterial delivery of mesoangioblasts. 
Science. 2003; 301(5632): 487–92. 
PubMed Abstract | Publisher Full Text 
2. Sampaolesi M, Blot S, D'Antona G, et al.: Mesoangioblast stem cells ameliorate 
muscle function in dystrophic dogs. Nature. 2006; 444(7119): 574–9. 
PubMed Abstract | Publisher Full Text 
3. Diaz-Manera J, Touvier T, Dellavalle A, et al.: Partial dysferlin reconstitution by 
adult murine mesoangioblasts is sufficient for full functional recovery in a 
murine model of dysferlinopathy. Cell Death Dis. 2010; 1: e61. 
PubMed Abstract | Publisher Full Text | Free Full Text 
4. Tedesco FS, Hoshiya H, D'Antona G, et al.: Stem cell-mediated transfer of a 
human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med. 
2011; 3(96): 96ra78. 
PubMed Abstract | Publisher Full Text 
5. Kiskinis E, Eggan K: Progress toward the clinical application of patient-specific 
pluripotent stem cells. J Clin Invest. 2010; 120(1): 51–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
6. Grskovic M, Javaherian A, Strulovici B, et al.: Induced pluripotent stem cells–
opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 
2011; 10(12): 915–29. 
PubMed Abstract | Publisher Full Text 
7. Yamanaka S: Induced pluripotent stem cells: past, present, and future. Cell 
Stem Cell. 2012; 10(6): 678–84. 
PubMed Abstract | Publisher Full Text 
8. Tsuji O, Miura K, Okada Y, et al.: Therapeutic potential of appropriately 
evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl 
Acad Sci U S A. 2010; 107(28): 12704–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Zhao T, Zhang ZN, Rong Z, et al.: Immunogenicity of induced pluripotent stem 
cells. Nature. 2011; 474(7350): 212–5. 
PubMed Abstract | Publisher Full Text 
10. Ishikawa K, Toyama-Sorimachi N, Nakada K, et al.: The innate immune system 
in host mice targets cells with allogenic mitochondrial DNA. J Exp Med. 2010; 
207(11): 2297–305. 
PubMed Abstract | Publisher Full Text | Free Full Text 
11. Prigione A, Hossini AM, Lichtner B, et al.: Mitochondrial-associated cell death 
mechanisms are reset to an embryonic-like state in aged donor-derived iPS 
cells harboring chromosomal aberrations. PLoS One. 2011; 6(11): e27352. 
PubMed Abstract | Publisher Full Text | Free Full Text 
12. Boyd AS, Higashi Y, Wood KJ, et al.: Transplanting stem cells: potential targets 
for immune attack. Modulating the immune response against embryonic stem 
cell transplantation. Adv Drug Deliv Rev. 2005; 57(13): 1944–69. 
PubMed Abstract | Publisher Full Text 
13. Wood KJ, Goto R: Mechanisms of rejection: current perspectives. 
Transplantation. 2012; 93(1): 1–10. 
PubMed Abstract | Publisher Full Text 
14. Tedesco FS, Gerli MF, Perani L, et al.: Transplantation of genetically corrected 
human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. 
Sci Transl Med. 2012; 4(140): 140ra89. 
PubMed Abstract | Publisher Full Text 
15. English K, Tonlorenzi R, Cossu G, et al.: Mesoangioblasts suppress T cell 
proliferation through IDO and PGE-2-dependent pathways. Stem Cells Dev. 
2013; 22(3): 512–23. 
PubMed Abstract | Publisher Full Text | Free Full Text 
16. Tonlorenzi R, Dellavalle A, Schnapp E, et al.: Isolation and characterization of 
mesoangioblasts from mouse, dog, and human tissues. Curr Protoc Stem Cell 
Biol. 2007; Chapter 2: Unit 2B.1. 
PubMed Abstract | Publisher Full Text 
17. Bartholomew A, Sturgeon C, Siatskas M, et al.: Mesenchymal stem cells 
suppress lymphocyte proliferation in vitro and prolong skin graft survival in 
vivo. Exp Hematol. 2002; 30(1): 42–8. 
PubMed Abstract | Publisher Full Text 
18. Boyd AS, Wood KJ: Characteristics of the early immune response following 
transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS 
One. 2010; 5(6): e10965. 
PubMed Abstract | Publisher Full Text | Free Full Text 
19. English K, Wood KJ: Immunogenicity of embryonic stem cell-derived 
progenitors after transplantation. Curr Opin Organ Transplant. 2011; 16(1): 90–5. 
PubMed Abstract | Publisher Full Text 
20. Hori J, Ng TF, Shatos M, et al.: Neural progenitor cells lack immunogenicity and 
resist destruction as allografts. Stem Cells. 2003; 21(4): 405–16. 
PubMed Abstract | Publisher Full Text 
21. Robertson NJ, Brook FA, Gardner RL, et al.: Embryonic stem cell-derived tissues 
are immunogenic but their inherent immune privilege promotes the induction 
of tolerance. Proc Natl Acad Sci U S A. 2007; 104(52): 20920–5. 
PubMed Abstract | Publisher Full Text | Free Full Text 
22. Swijnenburg RJ, Tanaka M, Vogel H, et al.: Embryonic stem cell immunogenicity 
increases upon differentiation after transplantation into ischemic myocardium. 
Circulation. 2005; 112(9 Suppl): I166–72. 
PubMed Abstract | Publisher Full Text 
23. Boyd AS, Rodrigues NP, Lui KO, et al.: Concise review: Immune recognition of 
induced pluripotent stem cells. Stem Cells. 2012; 30(5): 797–803. 
PubMed Abstract | Publisher Full Text 
24. Ren G, Zhang L, Zhao X, et al.: Mesenchymal stem cell-mediated 
immunosuppression occurs via concerted action of chemokines and nitric 
oxide. Cell Stem Cell. 2008; 2(2): 141–50. 
PubMed Abstract | Publisher Full Text
25. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al.: Sustained alpha-sarcoglycan 
gene expression after gene transfer in limb-girdle muscular dystrophy, type 
2D. Ann Neurol. 2010; 68(5): 629–38. 
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Mendell JR, Campbell K, Rodino-Klapac L, et al.: Dystrophin immunity in 
Duchenne’s muscular dystrophy. N Engl J Med. 2010; 363(15): 1429–37. 
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Mingozzi F, Meulenberg JJ, Hui DJ, et al.: AAV-1-mediated gene transfer to 
skeletal muscle in humans results in dose-dependent activation of capsid-
specific T cells. Blood. 2009; 114(10): 2077–86. 
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 10 of 12
F1000Research 2013, 2:24 Last updated: 24 MAR 2014
F1000Research
  Current Referee Status:
Referee Responses for Version 1
,  Mayana Zatz1 Antonio Condino-Neto2
 Human Genome and Stem-Cell Center, Institute of Biosciences, University of São Paulo, Sao Pãulo,1
Brazil
 Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil2
Approved: 24 February 2014
 24 February 2014Referee Report:
In this study Li, English  propose that HIDEMs behave in a very similar manner to mesoangioblasts,et al.
with regard to expression of HLA and co-stimulatory molecules, suppressive potency and mechanisms
of action. HIDEMs are comparable to mesoangioblasts in their surface marker expression and that both
cell populations respond to stimulation with pro-inflammatory cytokines consistently, with increased
expression of HLA-ABC, HLA-DR, PD-L1 and low level expression of CD40. Importantly, HIDEMs
suppress T cell proliferation driven by anti-CD3/CD28 stimulation in a similar dose-dependent manner as
that of mesoangioblasts, but with increased potency. Comparable to mesoangioblasts, HIDEMs did not
alter the expression of early activation markers CD25 or CD69 on CD3+ T cells, a phenomenon also seen
with immune-suppressive mesenchymal stromal cells (MSC). These findings are comparable to other
publications by the same group.
 
The activation step involving IFN-γ or TNF-α is an apparent prerequisite for HIDEM suppression of T cell
proliferation as neutralization of either cytokine significantly abolished the inhibitory effect. IDO and PGE-2
are identified as key mechanisms of action involved in HIDEM suppression of T cell proliferation.
 
Following this line of thinking we suggest that other potential suppressive mechanisms should be
investigated. The involvement of regulatory cytokines like IL-10, TGF-β for example should be addressed,
as well as the more detailed phenotype of T cells or even the participation of T regulatory cells should be
explored.
 
The detailed study of immunological mechanisms is highly relevant and may contribute to advance our
knowledge about the use of HIDEMs or mesangioblasts for the therapy of Duchenne muscular dystrophy.
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 Philippe Saas
Department of Immunology and Cell Therapy, University of Franche-Comté, Besançon, France
Approved: 31 January 2013
 31 January 2013Referee Report:
Page 11 of 12
F1000Research 2013, 2:24 Last updated: 24 MAR 2014
F1000Research
 31 January 2013Referee Report:
This is an interesting article reporting the  effect of human iPSC-derived mesoangioblasts on Tin vitro
cells. This is a prerequisite step in order to use these cells in the treatment of patients suffering from
muscular dystrophy.
How do human iPSC-derived mesoanglioblasts interact with T cells is an open question. This is of interest
since these cells can be used in cell-based therapy approaches. Immunogenicity of infused cells depends
on cell type.
The study by Li and colleagues is well performed. I have only minor comments in order to better explain
how the results on Figure #3AB are shown or calculated. 
Typo (page 3, paragraph “Results”): “makers” instead of “markers”.
I propose to add the number of experiments performed at the end of the legend of the Figure #1.
I suggest that the authors improve the Figure #3 panel A and B and its legend. For Figure #3A, I
understand well the two upper panels: the panel PBMC shows non proliferating PBMC (all the cells are
brightly stained with CSFE) and the panel PBMC + Anti CD3/CD28 shows maximal proliferation with all
the cells (gated for CD3) exhibiting decreased CSFE fluorescence due to CSFE dilution occurring during
cell division. I propose to modify the PBMC histogram and to increase the scale to better appreciate the
peak. According to the legend and the Materials and Methods section, the other panels correspond to the
coculture of either mesangioblast or iPSC-derived mesangioblast from a healthy donor or a patient with
PBMC (fixed number of 5 x 10 /well). Thus, the number of mesangioblasts varies and is decreasing (from4
1:4 to 1:32). It is logical that the peaks of proliferating CD3+ cells increase in the lower panels. However, if
inhibition of T cell activation occurs, a peak in the non dividing area/region should be observed as in the
panel “PBMC”. It seems to be the case for the condition “LMGMDD pt.3”. However, this is difficult to
observe with the other conditions. I propose to increase the Y scale. Maybe, as performed in the previous
Figure (Figure #2), counting beads were added to assess the absolute number of CD3+ CFSE  7AADlow
 cells. This explains why the peaks are flat in the 1:4 ratio conditions. Concerning Figure #3B, theneg
shown data represent the percentage of CD3+ cell proliferation in coculture divided by the percentage of
CD3+ cell proliferation in the absence of coculture. According to the upper panel of the Figure #3A, all the
cells proliferate. I suggest that the authors provide more explanations on how the data are obtained. 
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Page 12 of 12
F1000Research 2013, 2:24 Last updated: 24 MAR 2014
